The emergence of targeted alpha therapy for glioblastoma
Targeted alpha therapy shows promising preclinical results, increasing survival rate by 36.4 percent in recurrent tumours.
List view / Grid view
Targeted alpha therapy shows promising preclinical results, increasing survival rate by 36.4 percent in recurrent tumours.
At the heart of precision oncology is the need to increase our understanding and knowledge of surface proteins found on tumour cells. Here Roman Thomas, CEO of DISCO Pharmaceuticals, explains how it is using cutting-edge technology to explore the surfaceome – a map of the proteins on the cell’s surface…
Researchers have discovered that pancreatic cancer’s resistance to chemotherapy is related to the physical stiffness of the extracellular matrix.
Understanding how MMR-deficient colorectal cancers drive tumour growth and avoid immune detection could pave the way for personalised cancer medicine.
Molecular, cellular and metabolic analyses of liver biopsies identified markers that may predict subsequent metastasis of pancreatic cancer.
The tool identified patients with high-risk disease, which normally goes unrecognised by traditional diagnostics.
The inhibitor, HVH-2930, effectively induced apoptosis in breast cancer cells without initiating the heat shock response.
Researchers have developed a 3D approach to improve the characterisation of pancreatic intraepithelial neoplasias.
The algorithm can accurately diagnose cases of lung adenocarcinoma, determining structural features that are statistically most significant for assessing disease severity and likelihood of tumour recurrence.
In this Q&A, Associate Director, Research at Immunocore, Dr Ana Pereira Ribeiro, talks about IMC-R117C, a T cell receptor bispecific immunotherapy directed towards a novel target, PIWIL1, and about to enter Phase I testing in colorectal and gastrointestinal cancers.
The future of liquid biopsy is poised to revolutionise medical diagnostics and treatment. Explore the latest advancements and future prospects of liquid biopsy in our comprehensive eBook.
A new immunotherapy approach combining co-engineered T cells and antibodies enhances phagocytosis of tumour cells.
Through multi-omics analysis, researchers find that oestrogen signalling could be a target for never-smoker lung cancer cases.
Researchers discovered that HER2-positive breast cancer drugs must target both HER2 and EGFR receptors to eradicate disease.
In this Q&A, senior leaders at Caris Life Sciences discuss how the company is advancing precision medicine by integrating ADCs into patient-specific cancer treatment plans, focusing on novel target discovery through comprehensive molecular profiling and clinico-genomic data.